A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results

LBA68 Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with metastatic relapsed Ewing sarcoma (ES), on behalf of the French Sarcoma Group (FSG) and UNICANCER

(2020) F. Duffaud et al.   ANNALS OF ONCOLOGY

The Successful Treatment of Metastatic Extraosseous Ewing Sarcoma with Pazopanib

(2018) Yoshinori Mori et al.   INTERNAL MEDICINE

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

(2017) Hussein A Tawbi et al.   LANCET ONCOLOGY

Efficacy of Trabectedin in Patients with Advanced Translocation‐Related Sarcomas: Pooled Analysis of Two Phase II Studies

(2017) Mitsuru Takahashi et al.   ONCOLOGIST

Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial

(2016) Ethan Basch et al.   JOURNAL OF CLINICAL ONCOLOGY

Response of refractory Ewing sarcoma to pazopanib

(2014) Thierry Alcindor   ACTA ONCOLOGICA

Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy

(2014) Edwin Choy et al.   BMC CANCER

Pazopanib for recurrent extraosseous Ewing's sarcoma of the retroperitoneum

(2014) Yutaka Yamamoto et al.   INTERNATIONAL JOURNAL OF UROLOGY

Cyclophosphamide and Topotecan as First-line Salvage Therapy in Patients With Relapsed Ewing Sarcoma at a Single Institution

(2013) Rawad Farhat et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial

(2013) Gary K Schwartz et al.   LANCET ONCOLOGY

PARP-1 Inhibition as a Targeted Strategy to Treat Ewing's Sarcoma

(2012) J. C. Brenner et al.   CANCER RESEARCH

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

(2012) Winette TA van der Graaf et al.   LANCET

A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: A report from the Children’s Oncology Group

(2011) Sylvain Baruchel et al.   EUROPEAN JOURNAL OF CANCER

R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor, in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase II Sarcoma Alliance for Research Through Collaboration Study

(2011) Alberto S. Pappo et al.   JOURNAL OF CLINICAL ONCOLOGY

Angiogenesis and vascular targeting in Ewing sarcoma

(2009) Steven G. DuBois et al.   CANCER

Irinotecan and temozolomide for Ewing sarcoma: The Memorial Sloan-Kettering experience

(2009) Denise A. Casey et al.   PEDIATRIC BLOOD & CANCER

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER